Immunovia AB (publ) (0G8X)
Market Closed
7 Aug, 15:30
LSE 
kr
0. 17
-0.01
-5.275%
kr
- Market Cap
- P/E Ratio
- Div Yield
35,000 Volume
- Eps
kr 0.18
Previous Close Want to track 0G8X and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
0G8X closed Friday lower at kr0.17, a decrease of -5.275% from Thursday's close, completing a monthly decrease of -14.7475% or -kr0.03. Over the past 12 months, 0G8X stock lost -26.6087%.
0G8X is not paying dividends to its shareholders.
The last earnings report, released on May 07, 2026, exceeded the consensus estimates by 0.0311%. On average, the company has surpassed earnings expectations by 0.0233%, based on the last three reports.
Immunovia AB (publ) has completed 3 stock splits, with the recent split occurring on Oct 02, 2025.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on XSTO (SEK).
0G8X Chart
Immunovia AB (publ) (0G8X) FAQ
What is the stock price today?
The current price is kr0.17.
On which exchange is it traded?
Immunovia AB (publ) is listed on LSE.
What is its stock symbol?
The ticker symbol is 0G8X.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Immunovia AB (publ) ever had a stock split?
Immunovia AB (publ) had 3 splits and the recent split was on Oct 02, 2025.
Immunovia AB (publ) Profile
| Professional Services Industry | Industrials Sector | Jeff Borcherding CEO | LSE Exchange | SE0006091997 ISIN |
| SE Country | 9 Employees | - Last Dividend | 3 Feb 2026 Last Split | - IPO Date |
Overview
Immunovia AB (publ) is a pioneering diagnostic company that focuses on the development and commercialization of advanced blood-based diagnostics for cancer. Founded in 2007 and having its headquarters in Lund, Sweden, the company has made significant strides in providing innovative solutions not only within Sweden but also on a global scale. Immunovia’s mission revolves around the early detection of cancer, which is crucial for improving patient survival rates and outcomes. By leveraging cutting-edge research and technologies, the company aims to fill the gap in early cancer detection and contribute to the global fight against this life-threatening disease.
Products and Services
Immunovia’s portfolio primarily includes:
- IMMray PanCan-d: This is Immunovia’s flagship product, a blood-based test designed for the early detection of pancreatic cancer. The IMMray PanCan-d test utilizes a unique biomarker signature that can identify pancreatic cancer at an early stage, thereby potentially increasing the survival rates for patients diagnosed with this aggressive form of cancer. By offering a non-invasive and highly specific test, Immunovia addresses the critical need for early diagnosis in pancreatic cancer, which often presents with nonspecific symptoms and is typically diagnosed at an advanced stage.
Contact Information
Address: Medicon Village
Phone: 46 4 62 75 60 00
Website: https://www.immunovia.com
